Navigation Links
Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
Date:5/12/2008

cts will be recorded throughout the 24-hour period.

A second Phase 3 clinical trial is projected to begin in the third

quarter of 2008. The design of the second study will be similar to

the first trial, except that the patient population will be patients

with bipolar disease. AZ-004 has been licensed to Symphony Allegro,

Inc., and Alexza has the right to repurchase all rights to this

product candidate.

-- AZ-001 (Staccato prochlorperazine). Alexza is developing AZ-001 to

treat patients suffering from acute migraine headaches. In December

2007, the Company completed enrollment of a thorough QT clinical

trial, in which two doses of AZ-001 (5 and 10 mg) were compared to

active control and to placebo. The purpose of a thorough QT study is

to determine a drug's effect on cardiac rhythms. Based on a

preliminary analysis of the data from the study, neither of the doses

of AZ-001 produced a QT/QTc prolongation that would suggest an

increased risk of cardiac arrhythmia. The Company recently completed

a 28-day repeat dose inhalation study in dogs. Consistent with

previous findings in shorter-term and higher dose studies, the Company

observed dose-related minimal to slight metaplasia in the upper

respiratory tract, primarily in the nasal epithelium, in all treated

groups. These changes were partially reversible by the end of a

28-day post-treatment period. No lower respiratory tract or lung

findings were reported. Alexza has requested an end of Phase 2

meeting with the FDA for AZ-001.

-- AZ-104 (Staccato loxapine). Alexza is developing AZ-104 to treat

patients suffering from acute migraine headaches. AZ-104 is a lower

dose version of AZ-004. In March 2008, the Company announced positive

initial results o
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
2. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
3. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
4. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
5. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
6. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
7. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
8. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
9. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
10. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
11. MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... (PRWEB) September 20, 2014 Entries are ... Prism Awards for Photonics Innovation . The international ... multi-billion dollar optics and photonics industry, and is sponsored ... photonics , and Photonics Media . , The ... versatility of photonics, said SPIE CEO Eugene Arthurs. , ...
(Date:9/20/2014)... HealthTronics, Inc. , a ... products and services, has signed a distribution agreement ... Corporation for its high precision laser technology. ... invasive, mobile, surgical technology—offering more choices for healthcare ... HealthTronics will make available Clinicon’s FDA-cleared SureLase™ CO2 ...
(Date:9/20/2014)... September 20, 2014 MediVet America ... perform a groundbreaking surgery at the specialized Wolvega Horse ... superficial digital flexor tendon was ruptured 90% and her ... injury is a death sentence for a horse. , ... stem cell treatments . This revolutionary regenerative option ...
(Date:9/19/2014)... Sept. 19, 2014  InterMune, Inc. (Nasdaq: ... Memorandum of Understanding to settle the litigation in the ... Plan of Merger dated as of August 22, 2014, ... Inc.  As one term of the Memorandum of Understanding, ... forth in the attached exhibit reflecting the amendment to ...
Breaking Biology Technology:Entry deadline is 10 October for international photonics Prism Awards 2Entry deadline is 10 October for international photonics Prism Awards 3Entry deadline is 10 October for international photonics Prism Awards 4HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 2InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 5InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 6InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 7InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 8InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 9InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 10InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 11InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 12InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 13InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 14InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 15InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 16InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 17InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 18InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 19
... 25 Scimitar Equity, LLC issues a ... VOQP), entitled,"Creating Value; Turnaround Leverages Product Opportunities ... review is available at website: http://www.scimitarequity.com ... Jersey-based biotechnology company,dedicated to becoming a recognized ...
... 25 Mymetics,Corporation (OTC: MYMX), will be holding an ... PM New York Time to update all shareholders,on the ... Form 10-Q and to,address recent press articles., You ... at +1-866-591-4361 PIN 815,726 and from Europe at +41-800-329-326 ...
... 23 Eisai Corporation of,North America and its ... Food and Drug Administration (FDA) has approved a ... prevention of,chemotherapy-induced nausea and vomiting (CINV). ALOXI Capsules ... prevention of acute nausea and,vomiting following initial and ...
Cached Biology Technology:VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC 2FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting 2FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting 3
(Date:9/19/2014)... Durante of dinosaurs a newly discovered hadrosaur ... dinosaur, named Rhinorex condrupus by paleontologists ... University, lived in what is now Utah approximately ... period. , Rhinorex, which translates roughly into "King ... of other Cretaceous hadrosaurs like Parasaurolophus and Edmontosaurus. ...
(Date:9/19/2014)... researchers from several Harvard University labs in collaboration ... aspiring researchers with the intellectual raw materials needed ... soft, flexible materials. , With the advent of ... in manufacturing technology, soft robotics is emerging as ... conventional rigid robot design, but working with pliable ...
(Date:9/19/2014)... the unique bioelectric signaling system of the electric fish, ... The OU researcher is working to understand how these ... used to map the world around them. Electric ... discharges a second throughout their lives. The energetic ... necessary for survival. , "There is evidence that electric ...
Breaking Biology News(10 mins):New hadrosaur noses into spotlight 2Soft robotics 'toolkit' features everything a robot-maker needs 2
... Company Anticipates Acquisition Could More Than Double its Current ... the Medical and Healthcare Industry, SAN JOSE, Calif., ... a leading biometric and security,solutions provider, announced today the ... Medical Systems (OTC: CHSY), a company listed in,the US ...
... The gigantic fossil claw of an 390 million-year-old sea scorpion, ... insects, crabs and the like were surprisingly larger than ... O. Erik Tetlie , postdoctoral associate in the Department of ... of the report online in Royal Society Biology Letters. The ...
... Newly launched nerve cells in a growing embryo must chart ... use to navigate have yet to surface. In a study published ... Salk Institute for Biological Studies have recovered a key signal that ... spinal cord and must find their way down the length of ...
Cached Biology News:Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 2Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 3Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 4Salk scientists identify key nerve navigation pathway 2Salk scientists identify key nerve navigation pathway 3